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they would avoid medicines unless essential. Only 17% of
subjects suggested they would commence medication at the ﬁrst
sign of symptoms. Delays in seeking treatment up to 3 months
were reported by 26%, 3–6 months by 13% and >6 months by
24% of respondents. The age of symptom onset for those sub-
jects reporting constipation was 14–19 in 17%, 20–29 in 24%,
30–39 in 17%, and >40 in 23%. Eighteen percent of subjects
suggested that some health and personal conditions were too
embarrassing to discuss with their doctor. CONCLUSIONS: The
results are consistent with the opportunity for improving the role
of pharmacy services in managing constipation. Improved service
delivery in this sector might reduce the high proportion (68%)
seeking medical advice for their condition.
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OBJECTIVES: Alginates are often used ﬁrst line for gastroesoph-
ageal reﬂux disease (GORD). In the UK many primary care trusts
(PCTs) believe alginates to be interchangeable and discriminate
between products solely on cost. Consequently several PCTs have
implemented alginate substitution initiatives at the level of the
prescriber in an attempt to save costs. We sought to evaluate
whether PCT guidance suggesting alginate interchangeability
was reﬂected in a large longitudinal representative UK database
by comparing alginate switching patterns. METHODS: IMS
Disease Analyzer data was retrieved in which patients com-
mencing alginate monotherapy were followed for one year from
treatment initiation. From the dataset a cohort of 3367 patients
commencing therapy between June 1, 2005 and May 31, 2006
were tracked following their ﬁrst alginate prescription. Switching
patterns were analysed using chi-square and proportions tests for
the leading alginate brands: Gaviscon Advance (GA) and Peptac.
RESULTS: During the observation period 2238 and 1129 sub-
jects commenced GA and Peptac, respectively. After one year
87% of people on GA compared with 83% on Peptac were
maintained on their initial alginate (p = 0.013). Similar switching
rates were found when excessive switchers, deﬁned as more than
5 different interventions in one year, were removed from the
dataset (p = 0.04). Signiﬁcantly higher proportions of subjects on
Peptac (4%) switched to an alternative alginate compared with
those on GA (2%) (p < 0.005). The frequencies of observed
switching at the end of 12 months was different for those
started on GA and Peptac in the Pearson’s test of independence
(p = 0.039). Furthermore, subjects started on combination GA +
proton pump inhibitor (PPI) were more likely to discontinue PPI
at 12 months compared with those started on Peptac + PPI at
17% and 8%, respectively (p = 0.016). CONCLUSIONS: Sig-
niﬁcant differences in treatment failure were observed for the
leading UK alginates products. Additionally, patients initiated on
GA + PPI were more likely to discontinue their PPI compared
with persons treated with PPI + Peptac. These results highlight
the importance of considering a broader range of costs and
treatment factors impacting patients when introducing product
substitution policies.
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OBJECTIVES: The aim of this study was to gather epidemio-
logical data in a GERD population and to evaluate the added
value of the GERD Impact Scale (GIS) as a useful tool for patient
management of GERD. The GIS (score range 1–4) is a patient
questionnaire designed to aid physicians to identify the appro-
priate treatment and to evaluate the patient’s response to treat-
ment. METHODS: Patients from 296 centers with GERD and
esophagitis grade A to D (LA classiﬁcation) were included. The
physician decided at inclusion whether to initiate or change
the GERD treatment. Patients’ symptoms treatment changes and
GIS were assessed during the study. RESULTS: 2001 patients
(55 years, 52% female, BMI 26 kg/m2) were included. Median
interval between ﬁrst GERD onset and study entry was 1.2 years.
Twenty-ﬁve percent never received any treatment, 25% received
antacids, 25% H2-receptorblockers, 15% had received empiric
PPI therapy and 30% PPI following endoscopy. In 99% of cases,
physicians prescribed PPIs (esomeprazole [82%]) with a daily
dose of 40 mg. The dose was changed to 20 mg at visit 2 in 60%
of patients. The severity of GERD symptoms decreased through-
out the study with 89% of patients having moderate or severe
GERD in visit1, 31% in visit 2 and 14% in visit 3. Concurrently,
the GIS scores decreased signiﬁcantly (-1.18 for upper GI symp-
toms, -1.07 for other related GI symptoms and -0.96 for the
impact on life). GIS scores correlated signiﬁcantly but moderately
with the physician’s clinical judgment and weakly with endos-
copy ﬁndings. GIS was judged useful for 80% of patients. CON-
CLUSIONS: GIS scores improved with GERD PPI treatment and
were judged helpful by the physician. GIS may thus have an
added value over these assessments in determining the appro-
priate treatment and evaluating the patient’s response to this
treatment.
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OBJECTIVES: The aim of this observational study was to gather
epidemiological data not yet available in Luxembourg in a
primary care patient population with GERD with a history of
erosive esophagitis (3 years) and to evaluate the supposed
added value of the GERD Impact Scale (GIS) as a useful tool for
initial and follow-up long-term patient management of GERD.
The GIS (score range 1–4) is a novel patient questionnaire
designed to aid physicians to identify the appropriate treatment
and to evaluate the patient’s response to treatment. METHODS:
Consecutive patients from 20 study centers with symptomatic
GERD with or without esophagitis grade A to D (Los Angeles
classiﬁcation) were included. The physician decided at inclusion
whether to initiate or change the GERD treatment. Exclusion
criteria included current use of proton pump inhibitors (PPIs).
Patients’ symptoms, general evaluation by the physician, treat-
ment changes and GIS were assessed at baseline (visit 1) and
visits 2 and 3 (4–6 weeks and 8–14 weeks, respectively). Analyses
were performed on an intent-to-treat basis. GIS scores were
obtained by the physician at each visit. RESULTS: A total of 142
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